Ticker

Coloplast is rebased to a 20x P/E with a new price target of 490 DKK, reflecting a more realistic valuation post-premiumization. Recent setbacks—the Kerecis acquisition write-down, product recalls, and regulatory shifts—have driven shares down, but core fundamentals and inelastic product demand remain intact. CLPBY now trades at a historically low sub-18x P/E, offering a 5.76% yield and potential 12–13% annualized…

Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript